PulManage, Inc. has identified a substantial market opportunity in respiratory care, with a global addressable market (TAM) of $300 billion. The company aims to tackle various challenges in respiratory care, including accurate diagnosis, disease management, and access to real-time data trends for decentralized clinical trial data collection. Through its platform, PulManage is pioneering a new approach to care delivery by enabling remote respiratory biomarker collection and analysis. The core innovation lies in its ability to facilitate accurate diagnosis, remote monitoring for significant changes, and forecasting change in chronic respiratory conditions through data modeling. Ultimately, PulManage aims to enhance patient outcomes and significantly reduce healthcare costs, offering potential investors and partners a promising financial return.
